FDA accepts Tarceva NSCLC NDA

OSI (OSIP) said FDA accepted its NDA for Tarceva erlotinib as monotherapy to treat advanced non-small cell lung cancer (NSCLC) in patients in whom chemotherapy has failed. Separately, Tarceva was gran...